The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Biomarkers in Rheumatoid Arthritis Remain Elusive

Biomarkers in Rheumatoid Arthritis Remain Elusive

February 1, 2015 • By Kathy Holliman

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The researchers found evidence of four major phenotypes of RA synovium: lymphoid, myeloid, low inflammatory and fibroid, and each type has a distinct underlying gene expression signature. Baseline synovial myeloid, but not lymphoid, gene signature expression was higher in patients with good compared with poor EULAR clinical response to anti-TNFα therapy at Week 16. High baseline serum soluble intercellular adhesion molecule 1 (sICAM1), associated with the myeloid phenotype, and high serum C-X-C motif chemokine 13 (CXCL13), associated with the lymphoid phenotype, had different responses to anti-TNFα therapy (adalimumab) compared with responses to anti-IL6R therapy (tocilizumab). Patients with high sICAM1 and low CXCL13 had the highest ACR50 response rate at Week 24 to anti-TNFα monotherapy compared with patients with low sICAM1 and high CXCL13.

You Might Also Like
  • Letters: Biomarkers for Rheumatoid Arthritis
  • Progress Slow in Development of Useful Biomarkers for Rheumatoid Arthritis Treatment
  • Rheumatoid Arthritis Patients on Biologics Remain At Risk of Infection
Explore This Issue
February 2015
Also By This Author
  • Glucocorticoids a Fracture Risk at Any Dose

The researchers said that their data demonstrate that underlying molecular and cellular heterogeneity in RA affects clinical outcome to therapy. Patients with the myeloid phenotype exhibited the most robust response to anti-TNFα therapy in their study, suggesting a future pathway to identify and validate serum biomarkers that could predict response to targeted therapies, they concluded.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Timothy B. Niewold, MD, associate professor of medicine at Mayo Clinic in Rochester, Minn., presented research (Abstract 2927) at the 2014 ACR/ARHP Annual Meeting in Boston that looked at the association of circulating type I interferon levels and response to biologic therapies. Results of that research found that the increased pretreatment serum IFN-β:IFN-α inhibition ratio was strongly associated with nonresponse to TNFα inhibition by EULAR criteria at 12–14 weeks. IFN-β:IFN-α ratio greater than 1.3 was significantly more likely to have a nonresponse by EULAR criteria at 12 weeks, and no patient in the study with that ratio or greater achieved a good response. The conclusion was that the blood test may be useful in making treatment decisions about use of TNFα inhibitors in RA.

DAS scores simply measure current disease activity, & we need biomarkers that can predict response to therapy.

Dr. Ruderman describes that type of research as a fine example of “out-of-the-box” thinking that seems wise in the search for biomarkers. The researchers looked at interferon levels, interferon alpha and beta, “and it turns out the ratio of the two was helpful in predicting response to TNF inhibitor therapy, which you wouldn’t think of because it has nothing to do with TNF inhibitor therapy. Obviously the results have to be vetted, and it has to be replicated prospectively, but it was particularly useful at deciding who was unlikely to have a good response to a TNF inhibitor.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: Biomarkers, Holliman, Rheumatoid arthritisIssue: February 2015

You Might Also Like:
  • Letters: Biomarkers for Rheumatoid Arthritis
  • Progress Slow in Development of Useful Biomarkers for Rheumatoid Arthritis Treatment
  • Rheumatoid Arthritis Patients on Biologics Remain At Risk of Infection
  • Cure, Effective Treatment for Lupus Nephritis Remain Elusive Despite Advances

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)